Loading...
The FDA is renewing its efforts to “deal aggressively with opioid misuse and addiction” in the U.S. and at the same time “protect the well-being of people experiencing the devastating effects of acute or chronic pain.”
In a special report in the New England Journal of Medicine, FDA leaders outline steps the agency is taking toward those ends. Among them:
The agency will reexamine its current policies on opioid regulation. The FDA will work with the National Academy of Medicine (formerly the Institute of Medicine) to “develop a regulatory framework for opioid review, approval, and monitoring that balances individual need for pain control with considerations of the broader public health consequences of abuse and misuse.”
The FDA will reexamine c…